Using a cut-off value of 50.0 pg/mL for EphA2-NF and 37 U/mL for CA19-9, EphA2-NF and CA19-9 detected 96.9% (94/97) and 74.2% (72/97) of patients with pancreatic cancer (stages I/II/III/IV), 80.0% (4/5) and 20.0% (1/5) of patients with early-stage pancreatic cancer (stages I and II), and 96.1% (74/77) and 71.4% (55/77) of patients with late-stage pancreatic cancer (stage III/IV), respectively (Fig. 2E). Here, EPHA2 is linked to pancreatic neoplasm.